A.S. Dhadda

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Timothy Iveson, Rachel Kerr, Mark Saunders et al. · The Lancet Oncology · 2018 · 183 citations · Full text

Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial

Jean‐Pierre Gérard, N. Barbet, Renaud Schiappa et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 156 citations

Radiation Medicine, Surgical Oncology, Neoadjuvant Chemoradiotherapy +9

Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer

A.S. Dhadda, P. Dickinson, Abed M. Zaitoun et al. · European Journal of Cancer · 2011 · 80 citations

Adaptive Radiotherapy, Pre-operative Chemo/radiotherapy, Surgical Oncology +9

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial

Galina Velikova, Linda Williams, Sarah Willis et al. · The Lancet Oncology · 2018 · 80 citations · Full text

Quality Of Life, Surgical Oncology, Radiation Therapy +11